Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

Detalles Bibliográficos
Autores principales: Fowlkes, Ashley L., Yoon, Sarang K., Lutrick, Karen, Gwynn, Lisa, Burns, Joy, Grant, Lauren, Phillips, Andrew L., Ellingson, Katherine, Ferraris, Maria V., LeClair, Lindsay B., Mathenge, Clare, Yoo, Young M., Thiese, Matthew S., Gerald, Lynn B., Solle, Natasha Schaefer, Jeddy, Zuha, Odame-Bamfo, Leah, Mak, Josephine, Hegmann, Kurt T., Gerald, Joe K., Ochoa, Jezahel S., Berry, Mark, Rose, Spencer, Lamberte, Julie Mayo, Madhivanan, Purnima, Pubillones, Felipe A., Rai, Ramona P., Dunnigan, Kayan, Jones, John T., Krupp, Karl, Edwards, Laura J., Bedrick, Edward J., Sokol, Brian E., Lowe, Ashley, McLeland-Wieser, Hilary, Jovel, Krystal S., Fleary, Deanna E., Khan, Sana M., Poe, Brandon, Hollister, James, Lopez, Joanna, Rivers, Patrick, Beitel, Shawn, Tyner, Harmony L., Naleway, Allison L., Olsho, Lauren E.W., Caban-Martinez, Alberto J., Burgess, Jefferey L., Thompson, Mark G., Gaglani, Manjusha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Full Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942308/
https://www.ncbi.nlm.nih.gov/pubmed/35298453
http://dx.doi.org/10.15585/mmwr.mm7111e1

Ejemplares similares

Ejemplares similares